Tumor Challenge Assay
Tumor Challenge Assay - Related Videos
05:09
Repetitive Tumor Challenge Assay: An In Vitro Culture Assay to Evaluate Chimeric Antigen Receptor (CAR) T Cells for Repetitive Tumor Killing Potential
0 Views •
2025
In this video, we demonstrate the repetitive tumor challenge assay to evaluate the CAR T cells’ repetitive tumor killing potential during high tumor cell loads. Further, the CAR T cells can be analyzed using flow cytometry to determine the different subpopulations of CAR T cells in the sample.
07:53
An In vitro FluoroBlok Tumor Invasion Assay
0 Views •
Cited by 23 •
2009
This video demonstrates how to measure cell invasion through cell culture inserts using a fluorescence-based methodology.
12:19
Three-Dimensional (3D) Tumor Spheroid Invasion Assay
0 Views •
Cited by 213 •
2015
Invasion of surrounding normal tissues is a defining characteristic of malignant tumors. We provide here a simple, semi-automated micro-plate assay of invasion into a natural 3D biomatrix that has been exemplified with a number of models of advanced human cancers.
04:28
Lung Tumor Cell Recruitment Assay
0 Views •
2019
This manuscript describes a method to quantify tumor cell accumulation in the lungs in an animal model of tumor metastasis.
02:42
An In Vitro Assay to Evaluate the Anti-Tumor Activity of Tumor-Specific CAR T Cells
0 Views •
2025
This video demonstrates an in vitro assay to validate chimeric antigen receptor (CAR) T cell activity. B-cell lymphoma cells expressing CD19 antigen and cytoplasmic luciferase are co-cultured with CD19-specific CAR T cells. CAR binding to CD19 on a tumor induces the CAR T cells to release cytokines and toxins that cause tumor cell cytotoxicity. The CAR T cell activity is evaluated by quantifying the released cytokine and decreased luciferase-mediated bioluminescence in the tumor cells.
FAQs
Activated effector cells provide the immune component that can recognize and damage tumor cells. Their activity may be evaluated directly through target-cell lysis or indirectly through changes in tumor-cell viability and proliferation. Comparing responses under controlled culture conditions helps researchers determine whether an immune population produces measurable antitumor activity and how strongly that activity affects the target cells.
These components serve as distinct immune-based or therapeutic conditions for testing tumor control. Antibodies may be examined alongside immune cells, cytokines can be assessed for their influence on immune activity, and therapeutic agents can be evaluated for effects on tumor-cell survival or growth. Testing them separately or in combination helps reveal interventions that enhance or suppress antitumor responses.
Several readouts capture different aspects of the response: target-cell viability indicates survival, lysis reflects direct cell destruction, and proliferation shows whether tumor growth continues. Measurements of immune-cell activity add information about the responding effectors themselves. Using more than one readout can connect changes in tumor-cell outcome with the strength of the associated immune response.
Controlled culture conditions allow researchers to examine interactions between tumor cells, immune components, and interventions in a defined experimental setting. This makes it easier to attribute changes in viability, lysis, proliferation, or immune-cell activity to the tested condition. The resulting evidence can clarify factors that promote or restrain immune-mediated tumor control before comparison with molecular or in vivo studies.
A typical workflow brings tumor cells together with selected activated effector cells, antibodies, cytokines, or therapeutic agents under controlled culture conditions. Researchers then assess outcomes such as target-cell viability, lysis, proliferation, or immune-cell activity. The measured response is used to characterize antitumor activity and to compare how different immune-based or therapeutic conditions influence tumor control.
Researchers can use this assay to obtain functional evidence for cancer vaccines, cellular therapies, and combination treatments. It helps determine whether an intervention is associated with measurable tumor-cell control or altered immune activity. Because the model complements molecular and in vivo studies, it can connect mechanistic observations with a direct test of antitumor performance in culture.